IBS-QoL total scores and scores in the eight domains of the scale in placebo and FMT-treated patients
| Time | Group | Total score | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 0 | Placebo | 117.8±19.7 | 27.3±5.8 | 23.6±5.8 | 11.9±2.7 | 10.6±2.6 | 7.2±2.6 | 15.0±3.1 | 7.8±1.7 | 11.2±2.5 |
| 30 g FMT | 109.1±22.7 | 26.2±6.9 | 20.0±5.9** | 11.2±3.4 | 10.3±2.8 | 5.9±2.8 | 13.6±3.5 | 7.5±2.1 | 10.8±2.6 | |
| 60 g FMT | 113.4±22.4 | 27.4±6.7 | 21.4±5.5 | 11.5±2.8 | 10.6±2.7 | 6.7±2.8 | 14.1±3.4 | 7.7±1.7 | 10.8±2.8 | |
| 2 weeks | Placebo | 122.4±28.1 | 29.1±6.5 | 23.0±4.9 | 12.3±3.33 | 11.3±2.7 | 8.0±3.4 | 14.7±4.6 | 7.6±2.6 | 11.1±3.5 |
| 30 g FMT | 118.0±23.0 | 28.6±6.7 | 20.4±5.8* | 13.3±3.2 | 11.3±3.1 | 7.1±3.1 | 14.3±3.4 | 7.8±2.0 | 10.9±2.1 | |
| 60 g FMT | 124.5±25.1 | 31.1±6.6 | 23.3±5.9† | 13.4±3.7 | 12.0±2.7 | 8.3±2.8 | 15.5±3.5 | 8.1±1.9 | 11.7±2.7 | |
| 1 month | Placebo | 122.9±25.4 | 29.2±7.7 | 23.1±4.8 | 12.7±4.2 | 12.3±2.4 | 8.6±2.9 | 14.7±3.4 | 7.0±2.3 | 11.4±2.8 |
| 30 g FMT | 121.6±23.9 | 29.5±7.1 | 21.8±4.8 | 13.2±3.7 | 11.6±2.5 | 7.2±2.9* | 15.8±3.1 | 7.9±1.6 | 11.5±2.4 | |
| 60 g FMT | 127.7±25.5 | 31.1±6.7 | 23.0±5.1 | 13.9±3.5 | 12.1±2.4 | 8.6±3.3† | 15.1±3.9 | 8.2±2.0** | 11.7±2.8 | |
| 3 months | Placebo | 113.0±24.3 | 27.2±6.3 | 21.2±4.6 | 12.1±3.0 | 12.8±6.3 | 7.1±3.0 | 13.6±3.8 | 7.3±2.3 | 10.4±2.5 |
| 30 g FMT | 131.5±21.6*** | 32.1±6.9** | 24.1±5.2** | 14.0±3.0** | 12.6±2.9 | 8.8±3.2* | 16.1±2.6*** | 8.2±1.6* | 12.6±1.8**** | |
| 60 g FMT | 132.0±24.8*** | 32.5±6.7** | 24.0±4.7** | 14.5±3.4*** | 12.2±2.2 | 9.6±3.6*** | 15.7±3.5** | 8.3±1.6* | 12.1±2.6*** |
IBS-QoL domains: 1, dysphoria; 2, interference with daily activities; 3, body image; 4, health worries; 5, food avoidance; 6, social reaction; 7, sexual function; 8, impact on relationships.
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 compared with placebo.
†p<0.05 compared with 30 g FMT.
FMT, faecal microbiota transplantation; IBS, irritable bowel syndrome; IBS-QoL, IBS Quality of Life.